SPONSOR
Zhejiang Cancer Hospital
Total Trials
6
Recruiting
6
Phases
Phase 1, Phase 2, Phase 2
Conditions studied: HER2-positive Advanced Breast CancerMetastatic HER2 Positive Gastroesophageal Junction CancerPirtobrutinibSintilimabCentral Nervous System LymphomaTriple-negative Breast CancerBone MetastasesExtensive Stage Lung Small Cell CancerEfficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer
NCT05856383
Recruiting
Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC
HER2-positive Advanced Breast Cancer
NCT06650332 Phase 1, Phase 2
Recruiting
Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
Metastatic HER2 Positive Gastroesophageal Junction Cancer
NCT07416890 Phase 2
Recruiting
Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
Pirtobrutinib
NCT06538896 Phase 2
Recruiting
Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study
Triple-negative Breast Cancer
NCT06350162 Phase 2
Recruiting
Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC
Extensive Stage Lung Small Cell Cancer
NCT06562920 Phase 2
Recruiting
Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer
Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer